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Abstract  
 
Sutherlandia frutescens (SF) is one of the medicinal plants used as an immune booster in the treatment of chronic 
ailments such as HIV/AIDS and cancer. Limited data suggest that its efficacy is based on its regulatory effect on cytokines, 
the critical components of the immune response. In this study, we investigated the in vitro immunomodulatory effects of SF 
extracts on normal human peripheral blood mononuclear cells (PBMCs). An ELISA-based assay was used to assess the levels 
of expression of 12 cytokines in treated cells. An adenosine triphosphate (ATP) assay was used to assess cell viability in 
relation to cytokine secretion. SF ethanol extracts induced changes in cytokine secretion relative to the dose of the extract. 
Generally cytokine expression and secretion was low in concentration because were not stimulated with any endotoxin. The 
high SFE dose (2.5 mg/ml) significantly (p<0.001) decreased some cytokines including TNF-α and IL 1β. Low doses of this 
extract (0.5 mg/ml) did not change TNF-α and IL 1β secretion from the baseline (untreated cells). Changes in cytokine 
secretion of SFE treated cells tracked changes in ATP levels (cell viability). The SFW extract-induced changes in cytokine 
secretion were independent of cell viability. TNF-α was decreased (p<0.001) by the high dose of SFW extract while IL 1β 
and IFNγ were increased (p<0.01) by the same dose. High doses decreased cell viability which was reflected in cytokine 
secretion. It is evident, from these results, that SF extracts can modulate cytokine secretion in unstimulated normal PBMCs in 
vitro. Further studies in animal models are recommended to advance understanding of this immunomodulatory activity. 
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Introduction 
 
The use of African traditional medicine (ATM) in southern Africa has been shown to be on the rise as a result of 
the high prevalence of HIV/AIDS, tuberculosis (TB), malaria, cancer, diabetes and hypertension (Chabalala, 2008). The 
progression of these diseases is more rapid in patients with compromised immune system. One of the ATMs, Sutherlandia 
frutescens (SF) (Insizwa/Unwele in Zulu, or Cancer bush), is regarded as the most profound and multi-purpose medicinal 
plant in Southern Africa (Sia, 2004). Traditional healers usually prepare decoctions of SF according to the type of ailment 
pointed out by the patient. The preparation ranges from using each part of the plant alone (leaves, flowers, stems and roots) to 
using mixtures of these parts (van Wyk et al., 1997, van Wyk, 2008). Commercial preparations of SF have circumvented the 
need for preparing a mixture of the plant material with all the plants parts known to have active ingredients.  
Sutherlandia frutescens is postulated to act as an immunotonic and a supplement which assists the body in 
mobilizing its own immune response to fight infections and cope with mental stress. Despite its broad spectrum of 
applications, not enough reports have been published on the efficacy of this plant in fighting diseases as claimed by the 
healers (Mills et al, 2005). It is known for its efficacy and safety for use in many different health conditions (MRC, 2001; 
Johnson et al., 2007). Anecdotes have been provided from different clinical settings on how SF preparations improved the 
well-being and CD4+ cell counts in HIV/AIDS patients; and of how taking preparations of SF (commercial tablets, tea 
formulations, medicinal preparations from healers, etc) have greatly improved the well-being and CD4+ counts of HIV/AIDS 
sufferers (Jenkins, 2005). Tai et al. (2004) did not find any significant changes in secretion of cytokines (IL 1β and TNFα) 
caused by SF ethanol extracts in murine macrophage/monocytes RAW 264.7 cells. Cytokine secretion/expression is thought 
to play an important role in disease development and/or progression, especially in HIV/AIDS and cancer patients.  
Interleukin 1 is primarily produced by cells of the mononuclear phagocytic lineage but is also produced by 
oestoblasts, neutrophils, glial cells, and numerous other cells. One of the most important biological activities of IL 1 is its 
ability to activate T lymphocytes by enhancing the production of IL 2 and expression of IL 2 receptors. Interleukin 1 
augments B cell proliferation and increases immunoglobulin synthesis (Borish and Steinke, 2003). Interleukin 4 is an anti-
inflammatory cytokine that down-regulates both the innate and the adaptive immune responses. It is mainly produced by T 
cells, NK cells and mast cells and targets other T cells, eosinophils and endothelial cells for its regulatory actions (Alfano and 
Poli, 2005). Interleukin 6 is a key growth-promoting and anti-apoptotic inflammatory cytokine and is one of the effector 
signals of activated NF-қB in the promotion of neoplasia (Germano et al., 2008). Interleukin 8 is one of the most important 
chemo-attractants of neutrophils and its synthesis is enhanced by IL 1 (Borish and Steinke, 2003). Intereukin 10 inhibits the 
production of all pro-inflammatory cytokines and chemokines and the expression of dendritic cells co-stimulatory molecules, 
therefore shutting-off T-cell activation. Interleukin 10 levels have been found elevated in lymph nodes of HIV-infected 
individuals (Alfano and Poli, 2005). Tumour necrosis factor-α interacts with endothelial cells to induce adhesion molecules 
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known as intracellular adhesion molecule (ICAM)-1, vascular adhesion molecule (VCAM)-1, and E-selectin, thus permitting 
accumulation of granulocytes into inflammatory sites. Its pro-inflammatory actions allow for tumour regression by host 
immune reaction and inhibition of tumour angiogenesis (Minuzzo et al., 2007). 
The main aim of our study was to assess the immunomodulatory effects of SF ethanol and water extracts on normal 
human peripheral blood mononuclear cells (PBMCs). We achieved this by analysing the levels of cytokines and chemokines 
secreted by these cells in vitro. An ELISA-based multi-analyte assay was used to analyse for the secretion of a panel of 
twelve different cytokines (IL 1α, IL 1β, IL 2, IL 4, IL 6, IL 8, IL 10, IL 12, IL 17α, IFN-γ, TNF-α, and GM-CSF). The 
relationship between these cytokine effects and PBMCs viability was also investigated using a luminometry based ATP 
assay.       
 
 
Materials and Methods 
Reagents and equipment  
 
RPMI-1640 with HEPES buffer (25mM), foetal calf serum (FCS), penstrep-fungizone (PSF), and L-glutamine 
were purchased from Adcock Ingram (SA). Normal whole blood was obtained from the South African National Blood Supply 
(SANBS). Histopaque 1077 was purchased from Sigma Aldrich (SA). Ethanol was bought from Merck Chemicals (SA). 
Promega CellTiter-Glo™ Luminescent Cell Viability was purchased from Promega (SA). Sutherlandia frutescens tablets 
were bought from the local Chemist (Durban- SA). The Multi-Analyte Profiler ELISArrayTM Kit was purchased from 
SABiosciences (USA). Modulus™ Microplate Luminometer was from Turner BioSystems (USA). The 96-well plate reader 
was acquired from Bio-Tek (SA). 
 
Extraction of active ingredients from Sutherlandia frutescens tables 
 
Each of the SF tablet was extracted according to the method of Tai et al., (2004) with a slight variation. Briefly, SF 
tablets containing 300 mg of raw herb powder (per tablet) compounded with inert excipients were extracted with 2.2 ml of 
70% ethanol/triple distilled water at room temperature for 2 hours on an orbital shaker. The suspension was then centrifuged 
at 2 000g for 10 minutes and the supernatant was removed. The extracts were filter-sterilised twice using 0.45 µm filters to 
give a stock solution of 136.4 mg/ml of each extract type. These extracts were further serially diluted to 2.5, 1.5, 0.5 and 0.25 
mg/ml with complete culture medium (RPMI-1640 supplemented with 10% FCS, 1% L-glutamine, and 1% PSF). Both types 
of extracts were prepared on the same day of use. 
 
Isolation of peripheral blood mononuclear cells (PBMCs) from whole blood 
 
Normal whole blood from healthy volunteers (acquired from the SANBS in lithium heparin coated containers, 
ethics approval number EXP057/06) was carefully layered onto equal amounts of Histopaque 1077 then centrifuged at 400 g 
for 30 minutes at 25 °C. After centrifugation, the buffy coat layer, containing PBMCs, was isolated and washed twice in 
phosphate buffered-saline (PBS, 5 ml), (1150g for 20 minutes at 25 °C).The isolated PBMCs were diluted in RPMI-1640 and 
pooled into one tube. A cell count of 1.5- 2 × 106 cells/ml was determined using the trypan blue method to standardise the 
cell dilution.  
 
Treatment of PBMCs with Sutherlandia frutescens extracts 
 
Aliquots of the cell suspension (2 ml- 4 × 106 cells) were transferred into each well in a 6-multiwell plate. Doses of 
SF extracts (2 ml) were then added to each of the treatment wells. Vehicle control (70% ethanol) for the ethanol extract of 
SF, phytohaemagglutinin (PHA- 10 µg/ml) camptothecin (CPT, 20 µM) and untreated control wells were also included in the 
treatment setup as method controls. The 6-well plates were then incubated for 24 hours at 37 °C in a 5% CO2 incubator. 
 
Cytokine secretion assay 
 
The Multi-Analyte Profiler ELISArray assay kit (SA Biosciences, cat number: MEH-004A) is designed to be used 
with supernatants from treated cells or with serum from whole blood. It is a variation of the normal ELISA kit which uses 
absorbance instead of fluorescence to read the final results. The kit also does not give the exact concentration of each 
cytokine in pico or nanograms as a normal ELISA kit but differences in absorbance readings between controls and treated 
samples gives changes in cytokine secretion.  For the purpose of this research, cytokines were analysed from supernatants of 
treated PBMCs.  Each kit included 96-well plate coated with antibodies for the various cytokines in the microarray. Each row 
of the plate from 1 to 12 represented a single cytokines in the following order:  IL 1α, IL 1β, IL 2, IL 4, IL 6, IL 8, IL 10, IL 
12, IL 17α, IFN-γ, TNF-α, and GM-CSF. The kit had negative and positive method controls. Each sample was assayed in 
duplicate.   
Briefly, incubation of the samples in the 96-well plates allowed the capture antibodies to bind their specific protein 
of interest. After washing away unbound protein with wash buffer, biotinylated detection antibodies (50 µl) were added to the 
wells to also bind the captured analyte. Following another wash, an avidin-horseradish peroxidase conjugate (100 µl) was 
added. The wells were again washed and the colorimetric substrate solution was added, developing to a blue colour in direct 
proportion to the amount of protein analyte present in the initial sample. The colour development was stopped by adding the 
stop solution, and the absorbance was read at 450 nm with reference at 570 nm in a microplate reader as per manufacturer’s 
instructions.  
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Cell viability assay 
 
Following the incubation of treated cells for 24 hours, a 100 µl sample from each treatment concentration was 
pipetted into three different wells of a white opaque 96-well plate. The CellTiter-GloTM Reagent (Promega, cat number: 
G7570) was mixed immediately before use and was added to the wells with treated cells at 25 µl per well. The plate was 
shaken on a plate shaker for 2 minutes at 30 g. This plate was then incubated in the dark for 10 minutes at room temperature 
and the relative light units (RLU) of the samples were measured in a luminometer following the manufacturer’s instructions. 
A dose response curve was also generated for the ATP levels using the RLU and the dilutions of SF extracts and different 
control samples. 
 
Statistical analysis 
 
Data analyses were done on Microsoft Excel (Microsoft Corporation, City, USA) to obtain descriptive statistics.  
The different levels of significances within the separate treated groups were analysed using one-way analysis of variance 
(ANOVA) and the differences between the treated cells and the control cells (baseline) were analysed using GraphPad Instat 
software (version 3) with the Tukey-Kramer multiple comparison test. Differences with p≤0.05 were considered statistically 
significant. 
 
 
Results  
Cytokine expression 
 
Although these cytokines were expressed at low concentrations in all samples, the mean cytokine concentrations in 
the treated samples and the controls were statistically significant (Figures 1-3). Interleukin 1α levels decreased significantly 
in CPT treated supernatants (p< 0.001) and were unchanged in PHA treated samples (p> 0.05).  IL 1α levels were unchanged 
in SFE extract doses while it was significantly increased in the 2.5 mg/ml SFW dose (p< 0.001) as compared to the untreated 
control. The secretion of IL 1α was higher in SFW extract doses than in the SFE extract doses. A similar response was 
observed in IL 1β cytokine secretion although its concentration was higher relative to the others assayed in this group (Figure 
1). Expression of IL 2 in all control samples and SF extract treated samples did not show any significant changes (p> 0.05) 
(Figure 1). Interleukin 4 concentrations were unchanged in SF extract (SFE or SFW) treated samples when compared with 
the untreated control samples. The SFE extracts decrease IL 4 levels while this cytokine’s secretion did not change (0.5 
mg/ml) or increased (2.5 mg/ml) in the SFW extracts. However all these effects were not statistically significant (p> 0.05). 
Phytohaemagglutinin significantly increased (p< 0.001) IL 4 levels compared to all the various samples and controls (Figure 
1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Graphical illustration of changes in secretion of interleukins 1α, 1β, 2 and 4 in controls and Sutherlandia frutescens 
extracts treated samples. An ELISA-based kit was used to measure secretion of cytokines in cell supernatants and 
the results were obtained by measuring absorbance at 450 nm using a plate reader. The SFW doses increased the 
secretion of IL 1α & 1β while the high dose of SFE decreased both cytokines. A high dose of SFW also increased 
IL 4 secretion. In contrast, the secretion of all 4 cytokines was decreased in CPT treated cells, while PHA either 
showed no change or increased levels of all 4 cytokines. 
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Figure 2: Changes in secretion of IL 6, IL 8, IL 10, and IL 12 in controls and Sutherlandia frutescens extract dilutions treated 
samples. SF extracts decreased levels of IL 6 in all treated samples while similarly increasing the secretion of IL 8. A high 
dose of the SFE extract (2.5 mg/ml) significantly decreased IL 10 & 12 secretion. Both SFW doses showed a decrease in IL 
10 secretion. All cytokines were significantly decreased in the CPT treated samples while PHA did not change levels of any 
of these cytokine. 
 
Interleukin 6 concentrations in supernatants of all SF extract treated cells were significantly decreased when compared to the 
controls, with the SFE extracts being more effective in decreasing their secretion (p< 0.001) than SFW extracts (p< 0.01) 
(Figure 2). Interleukin 8 concentrations were significantly increased in all SF extracts treated samples (p< 0.001) when 
compared to the control samples. SFE extract significantly reduced (p< 0.001) and SFW extracts slightly (p< 0.01) reduced 
IL 10 secretion when compared to the untreated control. Concentrations of IL 12 did not change in either control or SF 
extract treated samples (p> 0.05) (Figure 2).  
High doses of both SF extracts (2.5 mg/ml SFE and SFW) significantly reduced the secretion of TNF-α in 
supernatants of treated PBMCs (p< 0.001). The low doses also decreased TNF-α levels but this was not statistically 
significant (p> 0.05). The levels of IFN-γ in SFE extract treated samples were unchanged while the SFW extract doses 
increased the secretion of this cytokine (p< 0.01) (Figure 3). The lower dilutions of the SF extracts reduced GM-CSF levels, 
but not significantly (p> 0.05) while the higher dilutions increased IL 17A (not significant, p> 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Changes in the secretion of IL 17α, IFNγ, TNF-α, and GM-CSF in controls and Sutherlandia frutescens extract 
dilutions treated samples. CPT treated samples significantly decreased all cytokines while PHA samples showed an 
increase in all cytokines. High dose of SFE (2.5 mg/ml) significantly decreased all cytokines but also caused 
increased cytotoxicity in PBMCs. SFW extracts decreased TNF-α secretion without the excessive cytotoxicity 
shown by the ethanol extract of SF. The SFW extract doses also increased secretion of IFN-γ, an important 
cytokine in fighting viral infections. 
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Changes in cell viability relative to cytokine expression  
     
ATP assay was performed to determine the cytotoxicity of SF extracts on the treated cells. Peripheral blood 
mononuclear cells treated with the camptothecin (20µM) had significantly reduced ATP levels (51%) when compared to 
theuntreated control cells (p< 0.001). The positive control (PHA, 10µg/ml) significantly increased ATP levels (161%) over 
the 24 hours (p< 0.001). The 70% ethanol vehicle control was not included in the cytokines analyses setup because it does 
not change the ATP levels (97%) when compared to the untreated PBMCs (p> 0.05) (Figure 4). The ethanol used for 
extraction did not play any statistically significant role in the effects of SFE extract dilutions on ATP levels in treated 
PBMCs. The high dose of the SF extracts (2.5 mg/ml SFE and SFW) significantly (p< 0.001) reduced the cell viability (25% 
and 60%, respectively) from the untreated baseline control. The 2.5 mg/ml SFE extract dose was more potent in reducing 
ATP levels than CPT (p< 0.001). The low dose of the SFE extract (0.5 mg/ml) significantly decreased the ATP levels (p< 
0.01). The 0.5 mg/ml SFW dose did not significantly change ATP levels (Figure 4). These results demonstrate increased 
cytotoxicity of higher doses of SF extracts on cultured normal PBMCs in vitro.   
 
 
 
 
 
Figure 4: Changes in cell viability of PBMCs treated with various doses of Sutherlandia frutescens extracts (SFE and SFW) 
over 24 hours. Conversion of the luminescence readings into a percentage cell viability change against the negative 
control showed that the high doses (2.5 mg/ml) of the SFE & SFW extracts induced a very significant decrease in 
cell viability. A low dose (0.5 mg/ml) of SFE induced a slightly significant decrease in ATP while the same SFW 
dose was not significant. It was also shown that the actions of the SFE extract doses were independent of ethanol 
(70% ethanol). PHA induced a significant increase in ATP levels while CPT decreased ATP levels significantly 
(p< 0.001).           
 
 
 
Discussion  
 
A study by Hendricks and Pool (2010) on the effects of Rooibos tea on immune cells showed that cytokines are 
expressed at very low concentrations in unstimulated immune cells while stimulation with endotoxin lipopolysaccharide 
(LPS) dramatically increase cytokine expression. This study was done on unstimulated PBMCs and therefore in agreement 
with above mentioned study on Rooibos tea. The results of this study have demonstrated that SF extracts can modulate 
cytokine expression in unstimulated treated PBMCs in vitro. The immunomodulatory ability of these SF extracts was 
dependent on the dose and type of the extract used. Cytokine secretion was also related to the cell viability. The chemical 
composition analyses of commercially available tablets of SF extracts has shown that this medicinal plant comprise several 
biological active compounds including L-canavanine, pinitol, gamma-aminobutyric acid, methyl- and propyl parabens and 
saponins, flavonol glycosides, triterpenoid saponins but no alkaloids (Tai et al., 2004; Stander et al., 2009; van Wyk and 
Albrecht, 2008).  Triterpenes are regarded as role players in the mechanism of action and pharmacological effects of many 
medicinal plants used against diseases in which the immune system is implicated. They are regarded as having anti-
inflammatory and immunomodulator compounds (Rios, 2010). 
Sutherlandia frutescens efficacy is demonstrated when it upregulates the secretion of IL 1 and IL 2. Interleukin 2 
production has been shown to be deficient in HIV infected individuals as well as after in vitro infection of PBMCs with HIV. 
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Due to the short half-life of IL 2, changes in the levels of this cytokine are not easy to assay directly (Alfano and Poli, 2005). 
One of the most important biological activities of IL 1 is its ability to activate T lymphocytes by enhancing the production of 
IL 2 and secretion of IL 2 receptors (Borish and Steinke, 2003). These findings support the notion that higher doses of SF 
extracts, which tend to reduce secretion of IL 1 cytokines, may suppress the immune response and its anti-inflammatory 
purpose. However, in our study the low doses of SF extracts which enhanced IL 1 cytokine secretion and therefore can be 
expected to stimulate the immune response.  
The increased secretion of IL 1β caused by the SFW extract contradict the results obtained by Tai et al., (2004). 
They found that there was no significant change or inhibition of IL 1β expression in RAW 264.7 macrophage cells treated 
with dilutions of an ethanol extract of SF. Although the experimental conditions were not similar, results in this current study 
demonstrate that SFW doses can increase IL 1β secretion. This pro-inflammatory cytokine, along with TNF-α, has been 
implicated in the cachexia seen in patients with HIV/AIDS. Agents that can reduce their production are thought be clinically 
useful. It was also observed that high doses of SFE extracts can reduce the levels of IL 1β.  The high SF doses also lowered 
the cell viability and therefore, could have negatively affected the IL 1β secretion. A dose-response assessment may be 
required to determine the right dose that gives the desired effects as demonstrated previously (Fernandes et al., 2004 and 
Kundu et al., 2005).  
The ability of SF extract dilutions to significantly decrease the levels of IL 6 may be a good indicator of SF 
efficacy. Interleukin 6 is a key growth-promoting and anti-apoptotic inflammatory cytokine and is one of the effector signals 
of activated nuclear factor- kappa (NF-қB) in the promotion of neoplasia (Germano et al., 2008). Depending on the type of 
cancer model, IL 6 activates different major pathways of cell proliferation, inducing tumour growth, metastasis, and 
resistance to chemotherapy (Salazar-Onfray et al., 2007). Therefore a decrease in this cytokine might negatively affect 
growth and metastasis of cancerous cells. 
The current study also demonstrated that SF extracts can suppress the secretion of IL 10.  This activity may result 
in the activation of T-cells and thus, the reduction of HIV replication. Increased levels of IL 10 inhibit the production of all 
pro-inflammatory cytokines and chemokines and the expression of dendritic cell-co-stimulatory molecules, therefore 
shutting-off T-cell activation (Alfano and Poli, 2005). Thus, the suppressing effect of SF on IL 10 is a positive indicator of 
SF extract efficacy. SF extracts, especially the SFW extract doses, increased the secretion of IFNγ in treated PBMCs 
regardless of dose level used. IFNγ is an important cytokine in the immune system’s response against viral infections (Parkin 
and Cohen, 2000). Thus, enhanced production of IFNγ stimulated by SF may be postulated as playing a role in reducing 
infections such as HIV.   
 Analysis of ATP levels was aimed at ascertaining whether cell viability had a role in the changes in the expression 
of cytokines in PBMCs. Some of the cytokines were up-regulated (i.e. IL 1α & 1β, IL 2, IL 8 and IFNγ) above or maintained 
to the levels of the untreated controls while ATP levels were shown to be depleted by high doses of the SF extracts (Figures 
1, 2, 3 & 4). These observations show that cytotoxicity (changes in ATP concentrations) of the SF extract doses was not 
directly related to the amount of cytokines secreted by the treated PBMCs. A possible exception to this would be the cells 
treated with the 2.5 mg/ml SFE extract dose. These cells secreted low levels of cytokines generally consistent with the 
decrease cell viability of treated PBMCs.                                                             
A number of studies have shown the cytotoxicity of SF extracts on cultured cell lines in vitro (Tai et al., 2004; 
Chinkwo, 2005; Stander et al., 2009; Korb et al., 2010). L-canavanine, a natural L-arginine analogue, and its metabolite 
canaline were suggested as two of many factors contributing to in vitro antiproliferative and apoptotic activity of SF extracts 
(Chinkwo, 2005).  Although our current study did not identify the exact active ingredients found in the SF tablet used in this 
study, it is postulated that the same ingredients could elicit the similar effects observed in the PBMCs as demonstrated by the 
luminometry ATP assay.  
 
Conclusion 
 
This study has shown that SF ethanol and distilled water extracts can modulate the expression of pro-inflammatory 
cytokines in treated PBMCs in vitro. High doses of SFE extract reduced secretion of IL 1α, IL 1β and TNF-α in treated 
PBMCs. The cell viability assay showed that extracts of SF can be cytotoxic to isolated lymphocytes and therefore negatively 
affect cytokine secretion. The results of this study warrant further investigation and animal studies are recommended to 
further elaborate our findings.  
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